Using a new technology and computational method, researchers have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers.

The process of transcription elongation by RNA polymerase II (Pol II), in which Pol II travels along DNA and synthesizes RNA from DNA, is essential for proper gene expression in all eukaryotic cells.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (”Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a ...

The 2nd ADC Payload Summit (May 6-8 | Boston, MA). This is the first and only conference exclusively focusing on ADC payloads ...

Announcing a new publication for Acta Materia Medica journal. Single-cell RNA sequencing (scRNA-seq) data from published datasets were obtained to investigate the expression and dysregulation of ...

TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...

Centrosomes are nonmembrane organelles and responsible for microtubule nucleation and organization. Centrosomal RNAs have been identified in diverse model systems and are known to regulate gene ...

Researchers at Fred Hutch and MD Anderson discovered RNA Polymerase II on histone genes as a biomarker for cancer ...

The new technology – Cleavage Under Targeted Accessible Chromatin (CUTAC) – focuses on small, fragmented DNA non-coding ...